147696-69-3Relevant academic research and scientific papers
Urea thiadiazole inhibitors of plasminogen activator inhibior-1
-
Page/Page column 21, (2010/02/11)
Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoisomer or solvate thereof, wherein: A is aryl o heteroaryl, and R1-R12, are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).
Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs
Fujita, Masakazu,Seki, Taketsugu,Inada, Haruaki,Shimizu, Kazuhiro,Takahama, Akane,Sano, Tetsuro
, p. 341 - 344 (2007/10/03)
A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxIs, such as Ridogrel (1).
6,6-Disubstituted hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors
Soyka,Heckel,Nickl,Eisert,Muller,Weisenberger
, p. 26 - 39 (2007/10/02)
A series of ω-disubstituted alkenoic acid derivatives were designed and synthesized as antithrombotic inhibitors of thromboxane A2 synthetase and thromboxane A2 receptor antagonists. Hexenoic acid derivatives with a 3- pyridyl group
